Vistagen FY2026 net loss $69.7M; PALISADE-4 topline results expected June 2026

Vistagen Therapeutics, Inc.

Net loss of $69.7M for FY ended March 31, 2026, vs $51.4M prior year; R&D expense $55.0M.
Cash and marketable securities $45.4M; management expects runway into 2027.
Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder; topline results expected in June 2026.
Received FDA 'Study May Proceed' letter for refisolone IND for menopausal hot flashes.
Appointed new CMO (Dr. Angel Angelov), CFO (Nick Tressler), and Chief Corporate Development Officer (Elissa Cote).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vistagen Therapeutics, Inc. reported fiscal year ended March 31, 2026 results: net income $69.7 million.

Period: fiscal year ended March 31, 2026
Net income: $69.7 million
Result: reported results

Exact text from the filing

Net loss was $69.7 million for the fiscal year ended March 31, 2026, compared with $51.4 million for the fiscal year ended March 31, 2025.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-043232

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.